news
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination…
22 October 2020 | By Hannah Balfour (Drug Target Review)
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination and loss in a murine model of multiple sclerosis (MS).